(Reuters)—Drugstore chain CVS Health Corp on Wednesday launched a new tool that will allow pharmacies help customers tackle the soaring cost of drugs by comparing prices of medicines. U.S. healthcare companies, ranging from insurers to drug retailers, are stepping up efforts to combat rising drug prices that has been widely criticized by regulators and has…
ACR Named a Top Atlanta Workplace for 2nd Consecutive Year
In a designation based on employee opinion, the ACR has been named one of the top places to work in Atlanta for the second year in a row. The honor is “a testament to the supportive and enthusiastic environment that we foster,” says ACR Executive Vice President Mark Andrejeski…
FDA to Review Abuse Deterrent Oxycodone Capsule & More
The FDA will discuss a New Drug Application for Remoxy ER during an upcoming advisory committee meeting and recently approved tildrakizumab-asmn to treat adults with plaque psoriasis…
Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
A recent systematic review found no clear evidence that rheumatoid arthritis patients treated with cyclophosphamide have better lung function than those treated with mycophenolate mofetil. The researchers caution that physicians should expect treatment with cyclophosphamide may only result in a modest improvement in the preservation of forced vital capacity…
AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023
(Reuters)—AbbVie Inc. on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc. that would fend off U.S. competition of their biosimilar version to blockbuster drug, adalimumab (Humira), until 2023. This is the second deal AbbVie has signed over the past year as it tries to safeguard patents on Humira,…
The ACR Updates Biosimilar Position Statement
In March, the ACR released a white paper designed primarily to help rheumatologists and rheumatology health professionals gain an understanding of biosimilars.1 This research-based education piece examines the scientific, economic and prescribing issues related to the use of biosimilars. Now, the ACR has released an update to its official position statement on the use of…
Arkansas PBM Bill: A Step in the Right Direction
During a three-day special legislative session in March, Arkansas Governor Asa Hutchinson (R) signed into law the first bill in the U.S. intended to address a lack of transparency among pharmacy benefit managers (PBMs) and their role in the high cost of prescription drugs.1 The bill, H.B. 1010: Arkansas Pharmacy Benefits Manager Licensure Act, will…
Prior Authorizations Hurt Patients & Practices
The ACR was part of a 16-member collaboration that created a set of 21 principles on prior authorization and utilization management, intended to ensure that patients receive timely and medically necessary care and medications and reduce the administrative burdens. More than 100 other healthcare organizations support those principles. Now, the AMA has released the results…
Write Your Letter to the Editor: The ACR Makes It Easy
Elected officials and government entities make decisions every day that directly affect your practice and ability to treat patients. Although the ACR continues to be your eyes and ears in Washington, D.C., often the most effective agents of change are citizens, like you, who get involved in the legislative process. It’s easy to be an…
Make Advocacy a Healthy Habit: A Conversation with Christina Downey, MD
While growing up in California’s capital city, Sacramento, Christina Downey, MD, learned early on that it’s important to speak up for what’s important to her. When she completed her fellowship and joined the ACR in 2015, she found her way to the ACR’s Advocacy 101 program, which trains rheumatologists to become advocates in Washington, D.C.,…
- « Previous Page
- 1
- …
- 346
- 347
- 348
- 349
- 350
- …
- 814
- Next Page »